Effect of a New Antithrombotic Agent (Defibrotide) in Acute Renal Failure Due to Thrombotic Microangiopathy
- 1 January 1985
- journal article
- research article
- Published by S. Karger AG in Nephron
- Vol. 40 (2) , 195-200
- https://doi.org/10.1159/000190340
Abstract
8 patients with thrombotic microangiopathy were treated with a new antilfcrombotic agent, defibrotide. This drug displays considerable fibrinolytic and antithrombotic activity, and induces generation and release of a prostacyclin-like substance from vascular tissue. At admission all patients presented severe renal involvement and coagulation abnormäÄies. Neurological manifestations were present in 6. Defibrotide admiu&tration was followed by recovery of renal function in 6, disappearance of neurological Symptoms and coagulation abnormalities in all p9l!ajits. The use of defibrotide was not associated with side effects. On the basis of the results obtained in these patients, we suggest that defibrotide might be considered as a valuable drug in the management of patients with thrombotic microangiopathy.Keywords
This publication has 6 references indexed in Scilit:
- Pharmacokinetics of defibrotide and of its profibrinolytic activity in the rabbitThrombosis Research, 1983
- PGI2-generation and antithrombotic activity of orally administered defibrotidePharmacological Research Communications, 1982
- Antithrombotic activity of a polydeoxyribonucleotidic substance extracted from mammalian organs: A possible link with prostacyclinThrombosis Research, 1981
- Aspirin and dipyridamole therapy in the hemolytic-uremic syndromeThe Journal of Pediatrics, 1980
- HqMOLYTIC-URqMIC SYNDROME: DEFICIENCY OF PLASMA FACTOR(S) REGULATING PROSTACYCLIN ACTIVITY?The Lancet, 1978
- Studies on the character and staining of fibrinJournal of Clinical Pathology, 1962